A small molecule drug being developed jointly by Galapagos NV and Laboratoires Servier has failed to meet the primary endpoint of a Phase 2 trial in patients with knee osteoarthritis (OA), the two companies announced on 15 October. The candidate treatment, GLPG1972, targets ADAMTS-5, an enzyme implicated in cartilage degradation. Osteoarthritis occurs when the protective cartilage that cushions the ends of bones wears down.
